Page last updated: 2024-10-19

phenethylamine and Brain Neoplasms

phenethylamine has been researched along with Brain Neoplasms in 1 studies

phenethylamine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7016
2-phenylethylamine : A phenylethylamine having the phenyl substituent at the 2-position.

Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.

Research Excerpts

ExcerptRelevanceReference
" We investigated the effects of dopamine in combination with platinum on human glioblastoma U-251MG cells upon X-ray irradiation, comparing with L-DOPA, 2-phenylethylamine and temozolomide."8.02Effects of platinum-coexisting dopamine with X-ray irradiation upon human glioblastoma cell proliferation. ( Kato, S, 2021)
" We investigated the effects of dopamine in combination with platinum on human glioblastoma U-251MG cells upon X-ray irradiation, comparing with L-DOPA, 2-phenylethylamine and temozolomide."4.02Effects of platinum-coexisting dopamine with X-ray irradiation upon human glioblastoma cell proliferation. ( Kato, S, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Kato, S1

Other Studies

1 other study available for phenethylamine and Brain Neoplasms

ArticleYear
Effects of platinum-coexisting dopamine with X-ray irradiation upon human glioblastoma cell proliferation.
    Human cell, 2021, Volume: 34, Issue:6

    Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; D

2021